Acorda Therapeutics, Inc.
Acorda Therapeutics, Inc. (ACOR) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
acor · stock forecast · 19 analysts (3M) · FMP · updated Jun 4, 2025
Analyst Rating & Consensus
Based on 19 Wall Street analysts in the past 3 months
Hold
19 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $0.88
Short-Term Price Prediction
BearAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $0.92 | ↑ 5.00% |
1-day model range: $0.89–$0.96. Peak: $0.96 (+5.00%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $0 | -50.0% |
| 2028 | $0 | -62.5% |
| 2029 | $0 | -67.2% |
| 2030 | $0 | -69.2% |
| 2031 | — | -70.2% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · ACOR · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2021-06-17 | HC Wainwright & Co. | Upgrade ↑ | Neutral→Buy |
| 2020-05-06 | H.C. Wainwright | Maintains | Neutral→Neutral |
| 2019-10-24 | JP Morgan | Downgrade ↓ | Neutral→Underweight |
| 2019-08-14 | H.C. Wainwright | Downgrade ↓ | Buy→Neutral |
| 2019-08-02 | Wedbush | Maintains | Neutral→Neutral |
| 2019-08-02 | Stifel | Maintains | Hold→Hold |
| 2019-05-23 | Wedbush | Maintains | Neutral→Neutral |
| 2018-12-11 | Goldman Sachs | Downgrade ↓ | Neutral→Sell |
| 2018-10-05 | Stifel Nicolaus | Maintains | Hold→Hold |
| 2018-08-23 | Cantor Fitzgerald | Maintains | Neutral→Neutral |
Wall Street analysts have recently issued updated ratings on Acorda Therapeutics, Inc. (ACOR) stock. Of the recent 44 rating actions, 5 were upgrades and 8 were downgrades. 19 analysts currently cover ACOR.
Analyst Recommendation Trends
ACOR analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$120M
↑ 8.5% YoY
Revenue Next Year
$121M
↑ 0.1% YoY
EPS This Year
$-152.80
EPS Next Year
$-19.20
↓ 87.4% YoY
EPS ForecastReported vs Estimated
Analysts forecast ACOR EPS of $-152.80 for the current fiscal year, based on estimates from 13 analysts. The ACOR revenue forecast is $120M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The ACOR stock forecast is supported by two independent data sources: analyst consensus ratings from 19 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ACOR price target is $0.00 (+0.0% upside), with an analyst consensus of Hold.
The ACOR short-term stock prediction for tomorrow is $0.92 (+5.00%). The ACOR stock price prediction for 2027 estimates an average of $0. The ACOR stock prediction for 2030 projects a range of $0–$0.
Acorda Therapeutics, Inc. trades on NASDAQ under the ticker ACOR. The ACOR stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 26% of covering analysts.
Frequently asked questions
ACOR forecast · 8 questionsAccording to 19 Wall Street analysts, the average 12-month ACOR price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $0.88.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.